Background: Targeted UVB phototherapy currently ranks among the most effective treatment options in localized vitiligo.
Introduction
Vitiligo is an acquired disorder of melanin pigmentation that affects about 1% of the world population [1] . The onset of this disease is seen before 15-years of age in majority of cases. Children affected with vitiligo suffer from psychological trauma with a profound effect on their quality of life [2, 3] .
On the therapeutic front, phototherapy with NBUVB has emerged as one of the most favoured treatment options in vitiligo. This treatment option has been found to be effective in both adult as well as childhood vitiligo with no significant adverse effects [4, 5] . Even combination therapies of NBUVB with topical and oral agents have been described with possible synergistic effects [6] [7] [8] . Targeted phototherapy is another advancement in this field wherein the phototherapeutic device specifically 'targets' the lesional skin while the rest of skin remains unexposed. Targeted phototherapy offers a number of advantages over whole-body NBUVB treatment as the photo-exposure remains strictly limited to the affected skin allowing higher energies to be delivered and minimizing the adverse effects of cumulative UVB irradiation on the body [8, 9] . Additionally, in comparison with traditional NBUVB therapy, Targeted phototherapy needs to be administered less frequently and the therapeutic results are obtained more rapidly as well [10, 11] . A number of targeted phototherapeutic devices have been used till date in vitiligo with encouraging results. These include XeCl excimer laser and lamp and targeted UVB devices delivering broadband UVB (BBUVB) or NBUVB light [11] [12] [13] [14] . Targeted UV light-based therapies employ conventional noncoherent ultraviolet light that is delivered through fibre-optic cable systems specifically to the treatment area. These machines deliver the light energy in seconds and have larger spot sizes [14] [15] [16] [17] .
Targeted phototherapy has been used successfully in childhood vitiligo as well. Clinical studies have demonstrated a good therapeutic effect of excimer laser monotherapy in childhood Vitiligo [18] . Excimer laser has even been used in combination with topical pimecrolimus in childhood vitiligo with good results [19] .
Material and Methods
Thirty-five children, with vitiligo involving less than 10% body surface area, were enrolled for the present study at our institute from May 2012 to August 2012. All the affected children were less than 15years of age and had a 'stable' disease at the time of enrolment into the study. For the purpose of the present study 'stable vitiligo' was defined as 'vitiligo showing no further spread or spontaneous re-pigmentation over a 3-month period'. If the patients were on any topical treatments, they were given a wash-out period of 3-weeks before enrolment into the study. Children who had received any other form of phototherapy in the past and those who had used any immunosuppressant's or immunomodulator drugs for vitiligo over the previous 1-month were excluded from the study. Additionally, children with photosensitive disorders and those with acrofacial vitiligo were also excluded. Acral lesions were excluded as they have been shown to be non-responsive to any form of phototherapy in clinical studies.
All the enrolled children were treated with a targeted phototherapy device named Levia R Professional Targeted UVB machine (Lerner Medical Devices Inc, USA) that delivers NBUVB light over 300 nm to 320 nm with a peak at 314 nm. The device delivers targeted NBUVB light in the range of 5 mJ/cm 2 to 800 mJ/cm 2 with a spot size of 3 square centimeters. The machine comes with a stencil of different shapes and sizes meant to treat similar-shaped or sized lesions. The machine also provides a separate attachment (Litebrush R ) to treat hairy areas like the scalp and chest/back in males.
All the enrolled children were given twice-weekly exposures with a gap of at least 48 hours in between two exposures. Lesions anywhere on the body including those on the eyes or genitals were treated but acral lesions were excluded as described above.
The initial dose used in every patient was 200 mJ/cm 2 and the energy was increased by 50 mJ/cm 2 after every dose till a faint erythema was obtained. The same dose was then continued till the patient continued to show mild erythema or perifollicular pigmentation. In case of eyelids and genital areas, the initial dose used was 100 mJ/cm 2 .
In case of painful erythema or blistering at any site, Targeted NBUVB treatment was stopped for 1 week and the dose was reduced by 50 mJ/cm 2 from the last dose received. No topical or oral drug therapy was allowed during the study period. All the children enrolled were followed up weekly for any evidence of re-pigmentation both clinically as well as by repeated digital photographs. Treatment was thus continued for a maximum of 30 sessions or complete repigmentation of treated lesions whichever occurred earlier. If there was no evidence of re-pigmentation by the 12 th dose of treatment or any koebnerization at the treatment site in the form of extension of vitiligo or any appearance of fresh lesions around the treatment area, Targeted phototherapy was stopped and patients were offered alternate treatment options.
The extent of re-pigmentation achieved was assessed visually in a manner as given in Table 1 . Re-pigmentation of >75% was labeled as 'excellent response' while 50-75% re-pigmentation constituted a 'good response'. Patients achieving <50% re-pigmentation were labeled as poor responders. Chi square test was used for assessing the statistical significance of the results obtained and a p value of <0.05 was considered as 'statistically significant'. Table 2 : Association of response with the site of vitiligo Three patients dropped out of the study after receiving just 1 to 3 doses. These patients could not continue twice weekly visits to our institute for treatment for personal reasons. Therefore, at the end of study period we had 32 children available for analysis of results ( Table  2 ). The age of enrolled children ranged from 6 years to 15 years with a mean of 11.7 years. Female sex was represented more as we had 20 females in comparison with only 12 males in the study group.
Extent of re-pigmentation Clinical Observation
Most of the patients were suffering from Vitiligo vulgaris and there were only 2 patients with segmental type of vitiligo (involving the face). Duration of vitiligo ranged from 6 months to 5 years with a mean of 2.3 years.
No serious adverse events were noted in any patient. Four patients developed intense mildly painful erythema, without blistering, at the treatment site. In all of these patients, treatment was stopped for one week and reintroduced at lower dose without any further adverse events. In total, there were 22 responders exhibiting >50% re-pigmentation at the treated sites. This accounted for 68.7% of all the cases available for analysis at the end of study period. Ten patients (31.3%) did not show a satisfactory response to treatment and were labeled as nonresponders.
Number of lesions treated in each patient ranged from 1 to 8. A total of 114 treated lesions were thus treated. Of these 48 lesions were located on the face and neck area, 34 on trunk, 6 on upper limbs and 26 on lower limbs. Acral areas, as mentioned earlier, were not treated and were thus excluded from the study analysis.
Out of the 48 lesions present on the face and neck, 35 lesions (72.9%) achieved >75% re-pigmentation (excellent response) while 7 others showed a good response with 50-75% re-pigmentation ( Figure  1a and 1b) . Thus only 6 lesions on the head and neck area failed to show a satisfactory response to Targeted NBUVB out of which 2 lesions were those of segmental vitiligo ( On the trunk, a total of 34 lesions were treated out of which excellent response was seen in 18 lesions (53%) while 7 and 9 lesions achieved a good and poor response respectively (Table 3) . Similarly, out of the 26 lesions treated on lower limbs, 6 lesions showed excellent response (23.1%) while 6 and 14 lesions showed good and poor response respectively. Lesions involving the upper limbs were underrepresented in this study and out of 6 lesions treated, 2 lesions achieved 75-100% re-pigmentation while the 4 others failed to show any significant response. Thus, out of 114 lesions treated on different body areas, excellent response was observed in 61 lesions (53.5%) while 20 others (17.5%) showed a good response. In total 52 lesions (45.6%) exhibited total or near-total re-pigmentation (Figure 2a and  2b) . No significant re-pigmentation (<50%) was seen in 33 lesions, accounting for 29% of the total lesions treated.
Figure 1b: Excellent response after 14 doses of Targeted NBUVB treatment
No untreated lesion in the study population showed any significant re-pigmentation over the study period and no extension of lesions was seen as well.
Onset of re-pigmentation in treated lesions was seen as early as the 4th dose of treatment in 14 cases. And by the 12th dose all those lesions which eventually re-pigmented, showed some evidence of pigmentation, either marginal or as perifollicular islands.
Number of Targeted NBUVB doses required to achieve complete re-pigmentation of the treated lesions ranged from a minimum of 8 doses given over 4 weeks to a maximum of 26 doses administered over a period of about 14 weeks. Thus, in some of the study cases the treatment was discontinued after just over a month because the treated An attempt was made to correlate the response achieved with the site of the treated lesions and the duration of vitiligo. Lesions on the face and neck area were seen to respond the best to the treatment regimen followed by trunk and lower limbs. While 72.9% of lesions achieved excellent response on face and neck area, the corresponding figure was 53% and 25% on the trunk and limbs respectively ( Table 3) .
The difference in the response between the different sites was tested for its statistical significance by means of chi-square test and the difference was found to be statistically significant (chi square value of 21.48 and p value of <0.001).
The response to treatment was also correlated with the duration of vitiligo. Re-pigmentation achieved in patients with different durations of vitiligo is shown in Table 4 . Difference in the response between the three groups was tested statistically by using the chi square test and was not found to be statistically significant ( with a chi square value of 4.78 and p value of 0.310). Children who responded to treatment were followed up for a period of 3 months after the end of treatment regimen to look for the stability of pigmentation achieved. None of them showed any loss of pigmentation over the treated areas in the follow up period.
Figure 2b: Excellent re-pigmentation after 24 doses of Targeted phototherapy

Discussion
Childhood vitiligo is always a challenge to manage as many of the treatment options that can be safely and easily used in adult population are either unsafe or impossible to use in children. Phototherapy with whole-body NBUVB chambers is practically difficult and at times impossible to administer in children especially at a young age. This disadvantage is not shared by Targeted phototherapy which is administered in a much more comfortable manner than traditional NBUVB therapy. Moreover, Targeted phototherapy also offers certain therapeutic advantages over wholebody NBUVB treatment especially for localized vitiligo [10, 12, 13] . Among targeted phototherapy devices currently available, excimer laser has been shown to induce the most rapid onset of repigmentation in vitiligo [11] . This phototherapeutic device has been shown to be effective in localized childhood vitiligo as well [18, 19] . In addition to excimer laser a monochromatic excimer lamp has also been utilized in the treatment of vitiligo with almost comparable results [12] .
As far as the targeted UVB devices are concerned, the UV spectrum delivered varies from one machine to another. These devices include 'BClear' that delivers broadband UVB, 'Multiclear' or 'Dualight' providing UVA and UVB combination and lastly 'Bioskin' which gives a NBUVB waveband peaking at 311nm [14] [15] [16] . Clinical studies have demonstrated that the results obtained are similar with the BB-UVB and NBUVB Targeted phototherapy devices in vitiligo [17] . In a clinical study conducted by Aswanonda et al., the overall response to the two different wavebands was seen to be similar at 12 weeks and this similarity was then maintained even at 24th week of treatment [17] . Targeted phototherapy with NBUVB is also known as 'microphototherapy'. The efficacy of this form of phototherapy has been demonstrated in both segmental as well as non-segmental vitiligo in adults [20, 21] . However, different authors have used different treatment schedules ranging from twice-weekly to once every two weeks treatment schedules. Both these treatment schedules have eventually led to significant therapeutic benefit in treated patients [20, 21] .
Studies on targeted phototherapy in childhood vitiligo are limited in number. In a study on excimer laser in childhood vitiligo, repigmentation of >50% was seen in 17 out of 30 patients (56.7%) treated with this modality [18] . Moreover, the response was seen to be site dependent, favoring the face, neck and trunk. No significant adverse effects were observed in this study.
Another study excimer laser monotherapy was compared with a combination of topical pimecrolimus and excimer laser treatment. In this study 71% patients achieved Grade 3 or 4 re-pigmentation with the combination treatment while only 50% patients achieved the same level of therapeutic benefit with excimer laser monotherapy [19] .
We have treated 35 children with NBUVB based targeted phototherapy in this study and we could achieve an excellent response in the form of >75% re-pigmentation in 53.5% of treated lesions. In addition, 17.5% more lesions showed a partial re-pigmentation of 50-75% taking the total percentage of responding lesions to 71%. This percentage is better than those quoted by earlier studies on Targeted phototherapy in childhood vitiligo [18, 19, 22] . We followed a twiceweekly schedule in our patients which is the one followed by majority of studies on Targeted phototherapy.
We could achieve an earlier onset of re-pigmentation in our patients, as early as at 4 th dose. This is more in conformity with the results achieved in vitiligo with excimer laser phototherapy than with the Targeted UVB devices described above. This difference can be explained probably on the basis of the difference in treatment schedule followed.
As with earlier studies, response to Targeted phototherapy in our study was seen to be site dependent with the head and neck regions responding the best to this modality (Table 4 ). This observation has been shared by almost all the clinical studies on this subject.
We did not treat acral lesions and we had just two patients of segmental vitiligo in our group. So the comparison between the therapeutic responses in different morphological types of vitiligo cannot be commented upon.
An important observation from our study was that any patient not showing any re-pigmentation to targeted UVB phototherapy by the 10 th or 12 th dose eventually showed a poor response to treatment. This observation is highly relevant clinically as it signifies that a patient is unlikely to respond to Targeted phototherapy if there is no evidence of re-pigmentation by the end of 6 weeks of treatment. Therefore, while administering this form of treatment in vitiligo, a period of 6-weeks should be enough to gauge whether a patient is expected to respond to treatment or not. Continuing the treatment beyond six weeks in such cases is highly unlikely to yield any positive results.
Conclusions
Targeted NBUVB phototherapy is an effective treatment option in childhood vitiligo with a rapid onset of re-pigmentation. The response to treatment is dependent on the site of the vitiligo lesion. Onset of repigmentation is expected to manifest within a maximum of 6 weeks.
